Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:11/7/2018
Start Date:May 2014
End Date:November 30, 2019
Contact:Holly Lee, GCTM
Email:holly.lee@ppdi.com
Phone:+1 612 581 2655

Use our guide to learn which trials are right for you!

A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer

In the dose escalation phase (Part 1), this study will determine the dose-limiting toxicities
(DLTs), the maximum tolerated dose (MTD) and recommended Phase 2 (RPII) dose of NC 6004 in
combination with gemcitabine.

In the expansion phase of the study (Part 2), study will evaluate the activity, safety, and
tolerability at the RPII dose identified in Part 1 in patients with squamous NSCLC, biliary
tract, and bladder cancer.


Inclusion Criteria:

- (Part 1 only) Have a histologically or cytologically confirmed diagnosis of advanced
solid tumor that has relapsed or is refractory to standard curative or palliative
therapy or has a contraindication to standard therapy.

- (Part 2 only) Cohort 1: Have histologically or cytologically confirmed diagnosis of
Stage IV squamous NSCLC and have not received prior chemotherapy or immunotherapy for
metastatic disease and are not known to be PD-L1 positive (known high PD-L1 expression
defined as Tumor Proportion Score [TPS] greater than or equal to 50%). Patients with
known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or
anaplastic lymphoma kinase (ALK) fusion oncogene must have received at least 1 and up
to 2 targeted therapies prior to enrollment.

- (Part 2 only) Cohort 2: Have histologically or cytologically confirmed diagnosis of
nonresectable, recurrent, or metastatic biliary tract carcinoma (intrahepatic or
extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) and have
not received prior systemic anticancer therapy for advanced or metastatic disease.

- (Part 2 only) Cohort 3: Have histologically or cytologically confirmed diagnosis of
metastatic or locally advanced TCC of the urinary tract (bladder, urethra, ureter,
renal pelvis) (T3b-T4 N0 M0, Tany N1-N3 M0, or Tany Nany M1) and are not candidates
for surgery.

- Have measurable disease per RECIST version 1.1.

- Have an ECOG PS of 0 to 1, with the exception of patients in Part 2 (Cohort 3, unfit
bladder cancer patients) who may have an ECOG PS of 2

- Adequate bone marrow reserve, liver and renal function

- Have a negative pregnancy test result at Screening for females of childbearing
potential

- Male patients must agree to use a condom during treatment and for 90 days after dosing
and must agree not to donate sperm for 90 days after dosing

- Women of childbearing potential are willing to agree to use 1 of the study defined
effective methods of birth control from the time of study entry to 6 months after the
last day of treatment

- Reasonably recovered from preceding major surgery as judged by the investigator or no
major surgery within 4 weeks prior to the start of Day 1 treatment

Exclusion Criteria:

- Have received prior platinum therapy in the past 3 months (Part 1) or 6 months in the
adjuvant or neoadjuvant setting (Part 2).

- Have received prior cisplatin and gemcitabine concomitantly within the last 6 months
or are refractory to cisplatin and gemcitabine.

- Unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment,
including investigational treatment

- Have evidence suggesting pulmonary fibrosis or interstitial pneumonia.

- Have a history of thrombocytopenia with complications

- Have known hypersensitivity to platinum compounds or gemcitabine.

- Have uncontrolled diabetes or have hypertension requiring more than 3 medications for
control of hypertension.

- Have pre-existing alcoholic liver injury or significant liver disease.

- Pregnant or breast feeding
We found this trial at
11
sites
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
303 E Chicago Ave
Chicago, Illinois 60611
(312) 503-8194
Northwestern University Feinberg School of Medicine Northwestern University Feinberg School of Medicine, founded in 1859,...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Encinitas, CA
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
San Francisco, California 94115
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Sofia,
Click here to add this to my saved trials